This finding could be relevant for treatment selection and personalized therapeutic approaches in AML as it implies that high-risk patients may be more sensitive to specific antitumor drugs, which targeted to PI3K–AKT–mTOR signaling pathways. The gene discussed is MTOR; the disease is acute myeloid leukemia.